ONO PHARMACEUTICAL CO.,LTD.

January10, 2019

Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma

This information is intended to notify the press release issued on January 8 (ET) by Karyopharm Therapeutics Inc. Please click http://investors.karyopharm.com/press-releases for the original press release distributed by Karyopharm.

1st paragraph of the press release:

NEWTON, Mass., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, requesting conditional approval for the treatment of patients with relapsed or refractory multiple myeloma (MM) who have received at least three prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody (mAb), and to their most recent treatment regimen (penta-refractory MM). Karyopharm also announced that the selinexor MAA has been granted accelerated assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP).

About the Ono and Karyopharm Collaboration

In October 2017, Ono Pharmaceutical Co., Ltd. concluded an exclusive license agreement with Karyopharm Therapeutics Inc. for the development and commercialization of Selinexor, their first-in-class oral XPO1 (Exportin 1) inhibitor, and Eltanexor/KPT-8602, a second-generation oral XPO1 inhibitor, for all oncology indications exclusively in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries.

Selinoxor (ONO-7705) is now under Phase I study in Japan for the treatment of multiple myeloma and non-Hodgkin lymphoma.

Contacts:
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp